{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT05095532",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Pro00099487"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "R01DK126454",
            "SecondaryIdType": "U.S. NIH Grant/Contract",
            "SecondaryIdLink": "https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01DK126454&Fy=all"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Medical University of South Carolina",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT",
      "OfficialTitle": "Autologous Mesenchymal Stromal Cells and Islet Co-transplantation to Enhance Islet Survival and Function in Chronic Pancreatitis Patients Undergo Total Pancreatectomy and Islet Autotransplantation"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2021",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 1, 2021",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 30, 2026",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 30, 2026",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "October 11, 2021",
      "StudyFirstSubmitQCDate": "October 25, 2021",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 27, 2021",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 22, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 23, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Hongjun Wang",
        "ResponsiblePartyInvestigatorTitle": "Professor, Scientific Director, Center for Cellular Therapy",
        "ResponsiblePartyInvestigatorAffiliation": "Medical University of South Carolina"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Medical University of South Carolina",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "CollaboratorClass": "NIH"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a clinical trial for non-diabetic chronic pancreatitis (CP) patients undergoing total pancreatectomy with islet autotransplantation (TP-IAT). Participants will be randomized to either bone marrow-derived mesenchymal stem cells (MSCs) or control with the standard of care. Participants will be followed for one-year post-transplant.",
      "DetailedDescription": "This will be a randomized, controlled clinical trial for CP patients scheduled to undergo a TP-IAT surgery. Those who are consented will be randomized into one of three groups. One group will receive islet transplantation alone, a placebo. The other two groups will receive islets plus autologous bone marrow-MSCs at two different doses (20x10^6/patient, or 50x10^6/patient). The TP-IAT procedure will remain as routinely performed. Patients will be followed for12 months post-transplantation, having 3 follow-up visits scheduled on days 90, 180, and 365 after the transplant. The primary endpoint will be a change in islet function from baseline to 12 months post-transplantation as measured by the C-peptide area under the curve following a mixed meal tolerance test. Potential effects of MSCs on glycemic control, pain relief, quality of life, and adverse events will be evaluated at each follow-up visit."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Chronic Pancreatitis",
          "Mesenchymal Stem Cells"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Total Pancreatectomy",
          "TP-IAT"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "This will be a randomized, controlled clinical trial in which non-diabetic CP patients scheduled for TP-IAT who meet the study criteria and consented will be randomized into three groups. One group will receive islet transplantation alone (n=14). The other two groups will receive islets plus BM-MSCs at two different doses (20x10^6/patient, or 50x10^6/patient, n=14 in each group).",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Care Provider",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "42",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "BM-MSCs at 20x10^6",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "One time infusion of islets plus BM-MSCs at 20x10^6/patient, n=14",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Bone marrow-derived mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "BM-MSCs at 50x10^6",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "One time infusion of islets plus BM-MSCs at 50x10^6/patient, n=14",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Bone marrow-derived mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "One time infusion of islets only.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Bone marrow-derived mesenchymal stem cells",
            "InterventionDescription": "MSC transplantation",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "BM-MSCs at 20x10^6",
                "BM-MSCs at 50x10^6"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Placebo",
            "InterventionDescription": "Standard of Care",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in Islet Cell Function",
            "PrimaryOutcomeDescription": "The primary endpoint will be change in islet function between baseline and 12 months as measured by area under the curve of C-peptide levels during a mixed meal tolerance test (MMTT) adjusted by islet equivalent number (IEQ) transplanted.",
            "PrimaryOutcomeTimeFrame": "1 year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in HbA1C levels from baseline to 12 months.",
            "SecondaryOutcomeDescription": "Change in HbA1C levels from baseline to 12 months",
            "SecondaryOutcomeTimeFrame": "1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Proportion of insulin-independent patients following IAT",
            "SecondaryOutcomeDescription": "Proportion of insulin-independent patients following IAT",
            "SecondaryOutcomeTimeFrame": "1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Average daily insulin requirement",
            "SecondaryOutcomeDescription": "Average daily insulin requirement",
            "SecondaryOutcomeTimeFrame": "1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Beta cell function as assessed by beta-score",
            "SecondaryOutcomeDescription": "β-score is an assessment of beta cell function after islet transplantation incorporating fasting plasma glucose levels, HbA1c, daily insulin, and stimulated c-peptide. The range of the score is from 0 to 8. Higher number means better beta cell transplant function.",
            "SecondaryOutcomeTimeFrame": "1 year"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Change in islet function between baseline to day 90±28",
            "OtherOutcomeDescription": "Change in islet function between baseline to day 90±28. Islet function will be indicated by area under the curve of C-peptide levels during a mixed meal tolerance test adjusted by islet equivalent number transplanted.",
            "OtherOutcomeTimeFrame": "90 days"
          },
          {
            "OtherOutcomeMeasure": "Daily oral Morphine Equivalents on day prior to visit",
            "OtherOutcomeDescription": "Daily oral Morphine Equivalents on day prior to visit (day 90±28 to day 365±28)",
            "OtherOutcomeTimeFrame": "9 months"
          },
          {
            "OtherOutcomeMeasure": "Proportion of patients remaining on narcotics",
            "OtherOutcomeDescription": "Proportion of patients remaining on narcotics (day 90±28 to day 365±28).",
            "OtherOutcomeTimeFrame": "9 months"
          },
          {
            "OtherOutcomeMeasure": "Short form (SF)-12 Quality of Life score",
            "OtherOutcomeDescription": "SF-12 Quality of Life score, Scores range from 0 to100, with higher scores indicating better physical and mental healthy functioning.",
            "OtherOutcomeTimeFrame": "1 year"
          },
          {
            "OtherOutcomeMeasure": "Glycemic control measured by area under the curve (AUC) HbA1c through year 1 and the C-peptide AUC and HbA1c AUC through year 1 (measured every three months) as impacted in a multivariate model by the IEQ/kg islets transplanted.",
            "OtherOutcomeDescription": "Glycemic control measured by area under the curve (AUC) HbA1c through year 1 and the C-peptide AUC and HbA1c AUC through year 1 (measured every three months) as impacted in a multivariate model by the IEQ/kg islets transplanted.",
            "OtherOutcomeTimeFrame": "1 year"
          },
          {
            "OtherOutcomeMeasure": "Incidence and severity of adverse events and serious adverse events",
            "OtherOutcomeDescription": "Incidence and severity of adverse events and serious adverse events",
            "OtherOutcomeTimeFrame": "1 year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosis of CP and scheduled for TP-IAT;\n≥18 years old;\nDiabetes-free before surgery as defined by the standards of the American Diabetes Association*.\nNo previous major pancreatic surgeries. Patients who have had minor surgeries including transduodenal sphincteroplasty or Whipple/Beger procedure are eligible.\n\nExclusion Criteria:\n\nPatients who are under immunosuppression;\nPregnant and breastfeeding women.\nPatients who have liver damage based on ALT, AST, and total bilirubin levels (>3 times normal levels);\nPatients who have had prior pancreatic surgeries including distal pancreatectomy or lateral pancreaticojejunostomy. We have observed that islet yield and function are negatively correlated with these types of pancreatic surgeries.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Meghan Blalock",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "843-792-2813",
            "CentralContactEMail": "schniedm@musc.edu"
          },
          {
            "CentralContactName": "Kelsey Cook",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "843 876 0420",
            "CentralContactEMail": "conder@musc.edu"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Charlton Strange, M.D",
            "OverallOfficialAffiliation": "Medical University of South Carolina",
            "OverallOfficialRole": "Study Director"
          },
          {
            "OverallOfficialName": "Katherine Morgan, M.D",
            "OverallOfficialAffiliation": "Medical University of South Carolina",
            "OverallOfficialRole": "Study Director"
          },
          {
            "OverallOfficialName": "Hongjun Wang",
            "OverallOfficialAffiliation": "Medical University of South Carolina",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "19104425",
            "ReferenceType": "background",
            "ReferenceCitation": "Sutherland DE, Gruessner AC, Carlson AM, Blondet JJ, Balamurugan AN, Reigstad KF, Beilman GJ, Bellin MD, Hering BJ. Islet autotransplant outcomes after total pancreatectomy: a contrast to islet allograft outcomes. Transplantation. 2008 Dec 27;86(12):1799-802. doi: 10.1097/TP.0b013e31819143ec."
          },
          {
            "ReferencePMID": "29289751",
            "ReferenceType": "background",
            "ReferenceCitation": "Morgan KA, Lancaster WP, Owczarski SM, Wang H, Borckardt J, Adams DB. Patient Selection for Total Pancreatectomy with Islet Autotransplantation in the Surgical Management of Chronic Pancreatitis. J Am Coll Surg. 2018 Apr;226(4):446-451. doi: 10.1016/j.jamcollsurg.2017.12.018. Epub 2017 Dec 28."
          },
          {
            "ReferencePMID": "30680957",
            "ReferenceType": "background",
            "ReferenceCitation": "Wang J, Zhang Y, Cloud C, Duke T, Owczarski S, Mehrotra S, Adams DB, Morgan K, Gilkeson G, Wang H. Mesenchymal Stem Cells from Chronic Pancreatitis Patients Show Comparable Potency Compared to Cells from Healthy Donors. Stem Cells Transl Med. 2019 May;8(5):418-429. doi: 10.1002/sctm.18-0093. Epub 2019 Jan 24."
          },
          {
            "ReferencePMID": "28854965",
            "ReferenceType": "background",
            "ReferenceCitation": "Song L, Sun Z, Kim DS, Gou W, Strange C, Dong H, Cui W, Gilkeson G, Morgan KA, Adams DB, Wang H. Adipose stem cells from chronic pancreatitis patients improve mouse and human islet survival and function. Stem Cell Res Ther. 2017 Aug 30;8(1):192. doi: 10.1186/s13287-017-0627-x."
          },
          {
            "ReferencePMID": "15677790",
            "ReferenceType": "background",
            "ReferenceCitation": "Ryan EA, Paty BW, Senior PA, Lakey JR, Bigam D, Shapiro AM. Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care. 2005 Feb;28(2):343-7."
          },
          {
            "ReferencePMID": "23411743",
            "ReferenceType": "background",
            "ReferenceCitation": "Wang H, Desai KD, Dong H, Owzarski S, Romagnuolo J, Morgan KA, Adams DB. Prior surgery determines islet yield and insulin requirement in patients with chronic pancreatitis. Transplantation. 2013 Apr 27;95(8):1051-7. doi: 10.1097/TP.0b013e3182845fbb."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010195",
            "ConditionMeshTerm": "Pancreatitis"
          },
          {
            "ConditionMeshId": "D000050500",
            "ConditionMeshTerm": "Pancreatitis, Chronic"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010182",
            "ConditionAncestorTerm": "Pancreatic Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M12267",
            "ConditionBrowseLeafName": "Pancreatitis",
            "ConditionBrowseLeafAsFound": "Pancreatitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M25413",
            "ConditionBrowseLeafName": "Pancreatitis, Chronic",
            "ConditionBrowseLeafAsFound": "Chronic Pancreatitis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M12254",
            "ConditionBrowseLeafName": "Pancreatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}